meglumine and Stomach Neoplasms

meglumine has been researched along with Stomach Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ando, Y; Hayashi, T; Imaizumi, K; Isaji, A; Ito, K; Kawada, K; Matsuda, H; Mine, N; Miyamoto, A; Naito, K; Nakanishi, T; Okada, T; Oya, M; Sakurai, K; Shibata, T; Suzuki, E; Takahashi, H; Uyama, I; Yamada, S	1

Trials

1 trial(s) available for meglumine and Stomach Neoplasms

Article	Year
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:2 Topics: Aged; Antiemetics; Aprepitant; Cisplatin; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Meglumine; Middle Aged; Morpholines; Nausea; Risk Factors; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome; Vomiting	2016

Article

Year

Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:2

Topics: Aged; Antiemetics; Aprepitant; Cisplatin; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Meglumine; Middle Aged; Morpholines; Nausea; Risk Factors; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome; Vomiting

2016